Dose not yet established because of experimental drug status. Also nausea, headache, diarrhea, vomiting, neutropenia, triglyceride elevation, and amylase elevation. T-cells did not go up significantly in trials, however. But another noted tenofovir's potential in the growing number of people whose triple-class therapy is failing. To its credit, tenofovir was successful in showing viral load decrease in people with nuke resistance.
Epivir resistance seems to reverse tenofovir resistance.
Also, because it's in a new drug class, tenofovir is not expected to have cross-resistance with other HIV medicines, and no new mutations were seen with its use in clinical trials. Unlike the nukes, nucleotides can enter uninfected cells, and once there, protect against infection. The body clears the drug through the kidneys, so watch creatine levels. So far, serious kidney problems have been rare. A lead-in dose is being tested to reduce side effects.